Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

@article{Hu2014MulticenterPI,
  title={Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.},
  author={Xi-Chun Hu and Jian Zhang and Binghe Xu and Zefei Jiang and Joseph Ragaz and Zhongsheng Tong and Qingyuan Zhang and Xiaojia Wang and Jifeng Feng and Danmei Pang and Minhao Fan and Jin Li and Bi Yun Wang and Zhonghua Wang and Qunling Zhang and S. F. Sun and Chunmei Liao},
  journal={International journal of cancer},
  year={2014},
  volume={135 8},
  pages={1961-9}
}
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase II study aims to evaluate the optimum dose level for the efficacy and safety of apatinib monotherapy in heavily pretreated patients with metastatic triple negative breast cancer (mTNBC) in China. Phase IIa was first performed among 25 patients previously treated with anthracycline and/or taxane. All patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Similar Papers

Loading similar papers…